Obesity causes lymphatic vascular injury: time for clinical translation

Barton, Matthias; Husmann, Marc

doi:10.1113/jp273253

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have investigated the influence of high fat diet induced obesity on lymphatic vascular function (Lim et al, 2009;Blum et al, 2014;Savetsky et al, 2014Savetsky et al, , 2015Barton and Husmann, 2016;Garcia Nores et al, 2016;Hespe et al, 2016;Nitti et al, 2016;Torrisi et al, 2016). They overwhelmingly conclude that obesity affects lymphatic vascular formation and function.…”

Section: High-fat Diet-induced Obesitymentioning

confidence: 99%

Lymphatic Vasculature in Energy Homeostasis and Obesity

Srinivasan

2020

Front. Physiol.

View full text Add to dashboard Cite

Obesity is a leading cause of cardiovascular diseases and cancer. Body mass is regulated by the balance between energy uptake and energy expenditure. The etiology of obesity is determined by multiple factors including genetics, nutrient absorption, and inflammation. Lymphatic vasculature is starting to be appreciated as a critical modulator of metabolism and obesity. The primary function of lymphatic vasculature is to maintain interstitial fluid homeostasis. Lymphatic vessels absorb fluids that extravasate from blood vessels and return them to blood circulation. In addition, lymphatic vessels absorb digested lipids from the intestine and regulate inflammation. Hence, lymphatic vessels could be an exciting target for treating obesity. In this article, we will review our current understanding regarding the relationship between lymphatic vasculature and obesity, and highlight some open questions.

show abstract

Section: High-fat Diet-induced Obesitymentioning

confidence: 99%

Lymphatic Vasculature in Energy Homeostasis and Obesity

Srinivasan

2020

Front. Physiol.

View full text Add to dashboard Cite

show abstract

Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges

Cignarella

Fadini

Bolego

et al. 2021

Cardiovascular Research

View full text Add to dashboard Cite

Vasoactive molecules, such as vascular endothelial growth factor (VEGF) and endothelins, share cytokine-like activities and regulate endothelial cell (EC) growth, migration and inflammation. Some endothelial mediators and their receptors are targets for currently approved angiogenesis inhibitors, drugs that are either monoclonal antibodies raised towards VEGF, or inhibitors of vascular receptor protein kinases and signaling pathways. Pharmacological interference with the protective functions of ECs results in a similar spectrum of adverse effects. Clinically, the most common side effects of VEGF signaling pathway inhibition include an increase in arterial pressure, left ventricular (LV) dysfunction ultimately causing heart failure, and thromboembolic events, including pulmonary embolism, stroke, and myocardial infarction. Sex steroids such as androgens, progestins, and estrogen and their receptors (ERα, ERβ, GPER; PR-A, PR-B; AR) have been identified as important modifiers of angiogenesis, and sex differences have been reported for anti-angiogenic drugs. This review article discusses the current challenges clinicians are facing with regard to angiogenesis inhibitor treatments, including the need to consider sex differences affecting clinical efficacy and safety. We also propose areas for future research taking into account the role of sex hormone receptors and sex chromosomes. Development of new sex-specific drugs with improved target and cell-type selectivity likely will open the way personalized medicine in men and women requiring antiangiogenic therapy and result in reduced adverse effects and improved therapeutic efficacy.

show abstract

Delta-like ligand 4 level in colorectal cancer is associated with tumor aggressiveness and clinical outcome

Zhang

Yan

et al. 2022

CBM

View full text Add to dashboard Cite

BACKGROUND: The Notch signaling regulates numerous cell growth, differentiation, and death. However, the expression pattern of its ligand Delta-like 4 (DLL4) in tumors is still uncertain. OBJECTIVE: In the present study, we examined DLL4 expression in colorectal cancer as well as assessed its role as a prognostic indicator in the present study. Methods: DLL4 expression was examined by immunohistochemistry in 265 surgically resected specimens of colorectal cancer and adjacent normal tissues. The relationship between DLL4 expression and clinicopathological characteristics was analyzed. The association of DLL4 expression with the patients’ overall survival rate was assessed by Kaplan-Meier and Cox proportional-hazards regression. RESULTS: Increased DLL4 level was detected in colorectal cancer compared with that of normal tissues. Elevated DLL4 level in colorectal cancer was associated with increased body mass index of patients. Moreover, increased DLL4 level was also found to be correlated with tumor invasion, metastases and unfavorable clinical outcom of patients. CONCLUSIONS: DLL4 level is increased in colorectal cancer, especially in patients with increased body mass index, indicating potential involvement of obesity-related tumorigenesis and development. It might also serve as a novel molecular marker to predicate outcome of patients.

show abstract

Obesity causes lymphatic vascular injury: time for clinical translation

Cited by 3 publications

References 21 publications

Lymphatic Vasculature in Energy Homeostasis and Obesity

Lymphatic Vasculature in Energy Homeostasis and Obesity

Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges

Delta-like ligand 4 level in colorectal cancer is associated with tumor aggressiveness and clinical outcome

Contact Info

Product

Resources

About